Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies
Allergy · 2024
DOI: 10.1111/all.15952 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Allergy, 2024. Verfasst von Peter Schmid-Grendelmeier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Asthma, Conjunctivitis, Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Abrocitinib efficacy by comorbidity status in patients with moderate‐to‐severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities.
Methods
Data were pooled from patients who received abrocitinib 200 mg, 100 mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials. Patients with and without allergic comorbidities (allergic asthma, rhinitis, conjunctivitis, or food allergy) were evaluated for Investigator's Global Assessment (IGA) response (clear [0] or almost clear [1]), ≥75% improvement in the Eczema Area and Severity Index (EASI‐75), ≥4‐point improvement in Peak Pruritus Numerical Rating Scale (PP‐NRS4), and Dermatology Life Quality Index (DLQI) response (1 allergic comorbidity, 34%). Regardless of comorbidity status, from Week 2 to Week 12, higher percentages of patients treated with either abrocitinib dose achieved IGA 0/1, EASI‐75, PP‐NRS4, or DLQI 0/1 versus placebo‐treated patients. Changes from baseline in POEM, SCORAD, and PSAAD were greater with abrocitinib than with placebo in patients with and without allergic comorbidities. Most TEAEs were mild or moderate.
Conclusions
Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
- SKiN Centre for Dermatology, Queen's University, and Probity Medical Research, Peterborough, Ontario, Canada.
- Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
- Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
- Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
- Pfizer Switzerland AG, Zurich, Switzerland.
ORCID-Profile: Peter Schmid-Grendelmeier, Melinda J Gooderham, Karin Hartmann, George N Konstantinou, Marc Fellmann, Claire Clibborn, Patrick M Brunner
Förderung
- Pfizer
Zitieren
APA
Schmid-Grendelmeier, P., Gooderham, M. J., Hartmann, K., Konstantinou, G. N., Fellmann, M., Koulias, C., Clibborn, C., Biswas, P., & Brunner, P. M. (2024). Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies. Allergy. https://doi.org/10.1111/all.15952
Vancouver
Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, Konstantinou GN, Fellmann M, Koulias C, et al. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies. Allergy. 2024. doi:10.1111/all.15952
BibTeX
@article{SchmidGrendelmeier2024,
author = {Schmid-Grendelmeier, Peter and Gooderham, Melinda J and Hartmann, Karin and Konstantinou, George N and Fellmann, Marc and Koulias, Christopher and Clibborn, Claire and Biswas, Pinaki and Brunner, Patrick M},
title = {Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.15952}
}
EUVIMED